Nice and judicial review: Enforcing 'accountability for reasonableness' through the courts?

Medical Law Review

Volumn 16, Issue 1, 2008, Pages 127-140

  Syrett, Keith ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DECISION MAKING; HEALTH SERVICE; HUMAN; LEGAL ASPECT; MEDICAL TECHNOLOGY; NATIONAL HEALTH SERVICE; NOTE; SOCIAL BEHAVIOR; UNITED KINGDOM;

DECISION MAKING; GREAT BRITAIN; HEALTH SERVICES; HUMANS; SOCIAL RESPONSIBILITY; STATE MEDICINE; TECHNOLOGY, MEDICAL;

EID: 40349100427     PISSN: 09670742     EISSN: 14643790     Source Type: Journal    
DOI: 10.1093/medlaw/fwm025     Document Type: Note

References (56)

1. K. Syrett, 'NICE Work? Rationing, Review and the "Legitimacy Problem" in the New NHS' (2002) 10 Med. L.R. 1-27.
2. T. Milewa and C. Barry, 'Health Policy and the Politics of Evidence' (2005) 39 Social Policy and Administration 498 at 502-503.
3. See e.g. 'NHS to Scrap Provision of Drugs for Alzheimer's Sufferers', Daily Telegraph, 1 March 2005.
4. At [31].
5. A. Maynard, 'Transparency in Health Technology Assessments' (2007) 334 B.M.J. 594.
6. [1985] A.C. 374.
7. Eisai, Final Appeal Document (15 June 2006) at para. 3.1, available at http://www. nice.org.uk/nicemedia/pdf/ Eisai_Final_Appeal_Document-15-June-2006.pdf (accessed 24 November 2007).
8. At [37] et seq.
9. At [61]-[62].
10. At [101].
11. At [112], citing NICE, Technology Appraisal Process: Guidance for Appellants (NICE 2004) at para. 3.4.1.
12. At [123].
13. At [124].
14. At [129]-[135].
15. At [136]-[138].
16. At [94]-[95].
17. At [3].
18. At [111].
19. See C. Newdick and S. Derrett, 'Access, Equity and the Role of Rights in Health Care' (2006) 14 Health Care Analysis 157.
20. See especially N. Daniels and J. Sabin, Setting Limits Fairly (Oxford University Press 2002).
21. See NICE, Social Value Judgements - Principles for the Development of NICE Guidance (NICE 2005) at para. 2.2.5.
22. For criticism that the Institute has misunderstood the model, see J. McMillan, M. Sheehan, D. Austin and J. Howell, 'Ethics and Opportunity costs: Have NICE Grasped the Ethics of Priority-Setting?' (2006) 32 Journal of Medical Ethics 127.
23. N. Daniels, 'Accountability for Reasonableness' (2000) 321 B.M.J. 1300.
24. Supra n.1.
25. See e.g. D. Longley, Public Law and Health Service Accountability (Open University Press 1993) at 7-8.
26. Health Committee, National Institute for Health and Clinical Excellence, HC503-II (2006-07), ev. 7 (NICE) at para. 8.
27. See also NICE, supra n.11 at para. 3.3.3.
28. At [62].
29. See Maynard, supra n.5 at 594 and,
30. more generally, S. Hill, 'Transparency in Economic Evaluations' (2005) 23 Pharmacoeconomics 967.
31. At [61].
32. At [19].
33. Health Committee, supra n.25, ev. 84 (Cancer Research UK) at para. 3.2-3.3
34. ev. 67 (Bristol-Myers Squibb Pharmaceuticals Limited) at para. 3.
35. Ibid. ev. 28 (Alzheimer's Society) at para. 3.6, 5.18
36. ev. 159 (MS Society) at para. 16-17.
37. At [43].
38. Supra n.1 at 22-23.
39. Supra n.7.
40. See S. Bryan, I. Williams and S. McIver, 'Seeing the NICE Side of Cost-Effectiveness Analysis: A Qualitative Investigation of the Use of CEA in NICE Technology Appraisals' (2007) 16 Health Economics 179.
41. A. Culyer, 'The Rationing Debate - Maximising the Health of the Whole Community - the Case For' (1997) 314 B.M.J. 667 at 667.
42. See e.g. R. Cookson and P. Dolan, 'Public Views on Health Care Rationing: A Group Discussion Study' (1999) 49 Health Policy 63
43. J. Coast, 'Is Economic Evaluation in Touch with Society's Health Values?' (2004) 329 B.M.J. 1233
44. P. Dolan, R. Shaw, A. Tsuchiya and A. Williams, 'QALY Maximisation and People's Preferences: A Methodological View of the Literature' (2005) 14 Health Economics 197.
45. Health Committee, supra n.25, ev.44 (Association of the British Pharmaceutical Industry) at para. 2
46. ev. 124 (Johnson & Johnson) at para. 4.1
47. ev. 141 (Lilly) at para. 20
48. ev. 178 (National Rheumatoid Arthritis Society) at para. 12.
49. See N. Daniels, 'Justice, Health and Healthcare' (2001) 1 American Journal of Bioethics 2 at 12.
50. At [112], [116], [131].
51. Health Committee, supra n.25, ev. 50 (AstraZeneca) at para. 2
52. ev. 60 (Bowel Cancer UK) at para. 5
53. ev. 111 (GlaxoSmithKline) at para. 3.15
54. ev. 156 (Merck Serono) at para. 16-17.
55. NICE Press Release 2007/042a, 10 August 2007 (A. Dillon).
56. See I. Williams and S. Bryan, 'Understanding the Limited Impact of Economic Evaluation in Health Care Resource Allocation: A Conceptual Framework' (2007) 80 Health Policy 135.